IP Library › Granted Patent US 12,397,055
Granted Patent B2
US 12,397,055 · App. 17/580,919 · Granted Aug 26, 2025

Methods of tumor vaccination

Inventors: Erik Hans Manting (Leiden, NL); Satwinder Kaur Singh (Leiden, NL); Jeroen Rovers (Leiden, NL)
Assignee: MENDUS B.V.
A61K40/42A61K40/19A61K40/24A61P35/00A61K2039/545A61K2039/55A61K2039/585A61K2039/892
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,055
App. No.
17/580,919
Granted
Aug 26, 2025
Kind
B2
Abstract

Provided herein are methods for treating a tumor or generating an immune response against a tumor in a subject in need, including one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition, and one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition. The first and second composition may each comprise an allogeneic leukemia-derived cell that is useful in eliciting an immune response against the tumor.

Claims (38)

1. A method for treating a tumor in a subject in need thereof, comprising:

one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of an allogeneic leukemia-derived cell, wherein the allogeneic leukemia-derived cell has a mature dendritic cell phenotype and is inactivated; and

one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of the allogeneic leukemia-derived cell;

wherein the allogeneic leukemia-derived cell comprises one or more exogenous tumor associated antigens or one or more nucleic acid molecules encoding the one or more exogenous tumor associated antigens.

2. The method of claim 1 , wherein the one or more intratumoral administration steps each comprises administering the first composition into the tumor or at a site proximal to the tumor, optionally wherein the site proximal to the tumor is peritumoral.

3. The method of claim 1 , wherein the first composition is prepared for intratumoral administration, optionally wherein the first composition comprises a diluent or solvent acceptable for intratumoral administration.

4. The method of claim 1 , wherein the one or more vaccination steps each comprise administering the second composition via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.

5. The method of claim 1 , wherein the one or more vaccination steps each comprises intravenously administering the second composition.

6. The method of claim 1 , wherein the one or more intratumoral administration steps are performed before the one or more vaccination steps.

7. The method of claim 6 ,

wherein

the one or more vaccination steps following the one or more intratumoral administration steps each comprise administering to the subject an effective amount of a third composition comprising an allogeneic leukemia-derived cell via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.

8. The method of claim 1 , wherein the time between the one or more intratumoral administration steps and the one or more vaccination steps is sufficient for an immune response to be mounted as a result of the one or more vaccination steps.

9. The method of claim 1 , wherein the one or more intratumoral administration steps are performed at the same time as the one or more vaccination steps.

10. The method of claim 7 , wherein the time between the one or more vaccination steps following the one or more intratumoral administration steps, and the one or more intratumoral administration steps is sufficient for an immune response to be mounted as a result of the first vaccination step of the one or more vaccination steps.

11. The method of claim 1 ,

wherein the exogenous tumor associated antigen is selected from the group consisting of WT-1, MUC-1, RHAMM, PRAME, p53, and Survivin, or

wherein the allogeneic leukemia-derived cell comprises WT-1, MUC-1, PRAME, and Survivin.

12. The method of claim 1 , wherein the allogeneic leukemia-derived cell is derived from the DCOne cell line.

13. The method of claim 1 , wherein the allogeneic leukemia-derived cell comprises a genetic aberration between chromosome 11p15.5 to 11p12, optionally wherein the genetic aberration encompasses about 16 Mb of genomic regions.

14. The method of claim 1 , wherein the allogeneic leukemia-derived cell is CD34-positive, CD1a-positive, CD83-positive, CD80-positive, CD86-positive, and CD40-positive.

15. The method of claim 1 , wherein the allogeneic leukemia-derived cell has been inactivated via irradiation.

16. The method of claim 7 , wherein the first composition further comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents,

the second composition further comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents, and/or

the third composition further comprises one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.

17. The method of claim 1 , wherein the subject has previously suffered from the tumor.

18. The method of claim 1 , wherein the tumor is a solid tumor.

19. A method for treating a tumor in a subject in need thereof, comprising:

one or more intratumoral administration steps each comprising administering to the subject an effective amount of an allogeneic leukemia-derived cell into the tumor or at a site proximal to the tumor, wherein the allogeneic leukemia-derived cell comprises a mature dendritic cell phenotype and is inactivated; and

one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of the allogeneic leukemia-derived cell via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue;

wherein the allogeneic leukemia-derived cell comprises one or more exogenous tumor associated antigens or one or more nucleic acid molecules encoding the one or more exogenous tumor associated antigens.

20. The method of claim 6 , wherein the one or more vaccination steps following the one or more intratumoral administration steps are administered via the same route as the one or more vaccination steps.

21. The method of claim 6 , wherein the one or more vaccination steps following the one or more intratumoral administration steps are administered via a different route as the one or more vaccination steps.

22. The method of claim 1 , wherein the time between the one or more intratumoral administration steps and the one or more vaccination steps is sufficient for an immune response to be mounted as a result of the first vaccination step of the one or more vaccination steps.

23. The method of claim 1 , wherein-the time between the one or more intratumoral administration steps and the one or more vaccination steps is about 2 days to about 21 days.

24. The method of claim 1 , wherein the one or more intratumoral administration steps are performed at the same time as the first vaccination step of the one or more vaccination steps.

25. The method of claim 7 , wherein the time between the one or more vaccination steps following the one or more intratumoral administration steps, and the one or more intratumoral administration steps is about 2 days to about 21 days.

26. The method of claim 7 , wherein the one or more vaccination steps following the one or more intratumoral administration steps, and the one or more intratumoral administration steps are performed at the same time.

Assignments (2)
CHANGE OF NAME Recorded May 16, 2023
From: DCPRIME B.V.
To: MENDUS B.V.
Reel/Frame 063663/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2022
From: MANTING, ERIK HANS; SINGH, SATWINDER KAUR; ROVERS, JEROEN
To: DCPRIME B.V.
Reel/Frame 059772/0436 →
Continuity (2)
Provisional Application 63140617 · Jan 22, 2021
Related Publication 20220249639A1 · Aug 11, 2022
References Cited (400)
US 4690915A · Rosenberg · 1987 [cited by applicant]
US 4797368A · Carter et al. · 1989 [cited by applicant]
US 4956778A · Naito · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5858358A · June et al. · 1999 [cited by applicant]
US 5876989A · Berg et al. · 1999 [cited by applicant]
US 5883223A · Gray · 1999 [cited by applicant]
US 5993434A · Dev et al. · 1999 [cited by applicant]
US 5994136A · Naldini et al. · 1999 [cited by applicant]
US 6013516A · Verma et al. · 2000 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6080840A · Slanetz et al. · 2000 [cited by applicant]
US 6181964B1 · Hofmann et al. · 2001 [cited by applicant]
US 6207156B1 · Kuchroo et al. · 2001 [cited by applicant]
US 6233482B1 · Hofmann et al. · 2001 [cited by applicant]
US 6516223B2 · Hofmann · 2003 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6567694B2 · Hayakawa · 2003 [cited by applicant]
US 6582959B2 · Kim · 2003 [cited by applicant]
US 6678556B1 · Nolan et al. · 2004 [cited by applicant]
US 6680301B2 · Berg et al. · 2004 [cited by applicant]
US 6692964B1 · June et al. · 2004 [cited by applicant]
US 6703020B1 · Thorpe et al. · 2004 [cited by applicant]
US 6797514B2 · Berenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6884879B1 · Baca et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7060269B1 · Baca et al. · 2006 [cited by applicant]
US 7067318B2 · June et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7171264B1 · Hofmann et al. · 2007 [cited by applicant]
US 7172869B2 · June et al. · 2007 [cited by applicant]
US 7173116B2 · Fewell et al. · 2007 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 7569664B2 · Jakobsen et al. · 2009 [cited by applicant]
US 7700546B2 · Mekada et al. · 2010 [cited by applicant]
US 7754482B2 · Riley et al. · 2010 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8017114B2 · Korman et al. · 2011 [cited by applicant]
US 8066989B2 · Lindhofer · 2011 [cited by examiner]
US 8119129B2 · Jure-Kunkel et al. · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8440431B2 · Voytas et al. · 2013 [cited by applicant]
US 8440432B2 · Voytas et al. · 2013 [cited by applicant]
US 8450471B2 · Voytas et al. · 2013 [cited by applicant]
US 8507443B2 · Mekada et al. · 2013 [cited by applicant]
US 8586363B2 · Voytas et al. · 2013 [cited by applicant]
US 8697853B2 · Voytas et al. · 2014 [cited by applicant]
US 8722400B2 · Riley et al. · 2014 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8771985B2 · Cui et al. · 2014 [cited by applicant]
US 9187758B2 · Cai et al. · 2015 [cited by applicant]
US 9206404B2 · Cui et al. · 2015 [cited by applicant]
US 9393257B2 · Osborn et al. · 2016 [cited by applicant]
US 9555105B2 · Riley et al. · 2017 [cited by applicant]
US 9855298B2 · Bot et al. · 2018 [cited by applicant]
US 9861689B2 · Mach · 2018 [cited by examiner]
US 10064923B2 · Van Wetering et al. · 2018 [cited by applicant]
US 10513686B2 · Ostertag et al. · 2019 [cited by applicant]
US 11027001B2 · Van Wetering et al. · 2021 [cited by applicant]
US 11052144B2 · Van Wetering et al. · 2021 [cited by applicant]
US 11071778B2 · Van Wetering et al. · 2021 [cited by applicant]
US 12091681B2 · Manting et al. · 2024 [cited by applicant]
US 20030170238A1 · Gruenberg et al. · 2003 [cited by applicant]
US 20030190317A1 · Baca et al. · 2003 [cited by applicant]
US 20030203409A1 · Kim · 2003 [cited by applicant]
US 20030206899A1 · Ferrara et al. · 2003 [cited by applicant]
US 20040014645A1 · Draghia-Akli et al. · 2004 [cited by applicant]
US 20040057935A1 · Yu · 2004 [cited by examiner]
US 20040059285A1 · Mathiesen et al. · 2004 [cited by applicant]
US 20040092907A1 · Mathiesen et al. · 2004 [cited by applicant]
US 20050052630A1 · Smith et al. · 2005 [cited by applicant]
US 20050070841A1 · Mathiesen et al. · 2005 [cited by applicant]
US 20050075308A1 · Wilson et al. · 2005 [cited by applicant]
US 20050112126A1 · Baca et al. · 2005 [cited by applicant]
US 20050186208A1 · Fyfe et al. · 2005 [cited by applicant]
US 20050196754A1 · Drmanac et al. · 2005 [cited by applicant]
US 20060009360A1 · Pifer et al. · 2006 [cited by applicant]
US 20060121005A1 · Berenson et al. · 2006 [cited by applicant]
US 20070041954A1 · Ichim · 2007 [cited by applicant]
US 20070128708A1 · Gamelin · 2007 [cited by applicant]
US 20120294796A1 · Johnson et al. · 2012 [cited by applicant]
US 20130274134A1 · Lindstedt et al. · 2013 [cited by applicant]
US 20130330399A1 · Reisfeld et al. · 2013 [cited by applicant]
US 20150166955A1 · Van Wetering et al. · 2015 [cited by applicant]
US 20150297698A1 · Van Wetering · 2015 [cited by examiner]
US 20180002397A1 · Shah et al. · 2018 [cited by applicant]
US 20180236054A1 · Sampson et al. · 2018 [cited by applicant]
US 20180346541A1 · Wong et al. · 2018 [cited by applicant]
US 20190000945A1 · Van Wetering et al. · 2019 [cited by applicant]
US 20190055297A1 · Zhao et al. · 2019 [cited by applicant]
US 20190134091A1 · Dropulic et al. · 2019 [cited by applicant]
US 20190151363A1 · Brentjens et al. · 2019 [cited by applicant]
US 20190263908A1 · Van Der Vliet et al. · 2019 [cited by applicant]
US 20200390876A1 · Manting et al. · 2020 [cited by applicant]
US 20200397883A1 · Manting et al. · 2020 [cited by applicant]
US 20210322471A1 · Manting et al. · 2021 [cited by applicant]
US 20210324332A1 · Manting et al. · 2021 [cited by applicant]
US 20210346479A1 · Van Wetering et al. · 2021 [cited by applicant]
US 20210401961A1 · Manting et al. · 2021 [cited by applicant]
US 20220023405A1 · Manting et al. · 2022 [cited by applicant]
US 20220023406A1 · Manting et al. · 2022 [cited by applicant]
US 20220168407A1 · Manting et al. · 2022 [cited by applicant]
US 20220249639A1 · Manting et al. · 2022 [cited by applicant]
US 20220305100A1 · Manting et al. · 2022 [cited by applicant]
US 20230355760A1 · Manting et al. · 2023 [cited by applicant]
US 20240002800A1 · Karlsson-Parra et al. · 2024 [cited by applicant]
CA 3104833A1 · 2020 [cited by applicant]
EP 0666868B1 · 2002 [cited by applicant]
EP 1894575B1 · 2013 [cited by applicant]
EP 2743344A1 · 2014 [cited by applicant]
EP 2931878B1 · 2016 [cited by applicant]
WO WO1994010202A1 · 1994 [cited by applicant]
WO WO1996007432A1 · 1996 [cited by applicant]
WO WO1996013593A2 · 1996 [cited by applicant]
WO WO1996018105A1 · 1996 [cited by applicant]
WO WO1996030046A1 · 1996 [cited by applicant]
WO WO1996040200A1 · 1996 [cited by applicant]
WO WO1998042752A1 · 1998 [cited by applicant]
WO WO1998045332A2 · 1998 [cited by applicant]
WO WO1999018129A1 · 1999 [cited by applicant]
WO WO2000037504A2 · 2000 [cited by applicant]
WO WO2000054708A1 · 2000 [cited by applicant]
WO WO2000054802A2 · 2000 [cited by applicant]
WO WO2001014424A2 · 2001 [cited by applicant]
WO WO2001018636A1 · 2001 [cited by applicant]
WO WO2001049317A2 · 2001 [cited by applicant]
WO WO2001093897A2 · 2001 [cited by applicant]
WO WO2002023994A1 · 2002 [cited by applicant]
WO WO2002044395A1 · 2002 [cited by applicant]
WO WO2002044396A1 · 2002 [cited by applicant]
WO WO2003020309A2 · 2003 [cited by applicant]
WO WO2004033685A1 · 2004 [cited by applicant]
WO WO2005012359A2 · 2005 [cited by applicant]
WO WO2005026318A2 · 2005 [cited by applicant]
WO WO2005040220A1 · 2005 [cited by applicant]
WO WO2005044853A2 · 2005 [cited by applicant]
WO WO2006000830A2 · 2006 [cited by applicant]
WO WO2006037960A2 · 2006 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007011693A2 · 2007 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009019320A2 · 2009 [cited by applicant]
WO WO2009034172A1 · 2009 [cited by applicant]
WO WO2009101611A1 · 2009 [cited by applicant]
WO WO2009114335A2 · 2009 [cited by applicant]
WO WO2009127988A1 · 2009 [cited by applicant]
WO WO2010037838A2 · 2010 [cited by applicant]
WO WO2011018636A2 · 2011 [cited by applicant]
WO WO2011044186A1 · 2011 [cited by applicant]
WO WO2012056236A2 · 2012 [cited by applicant]
WO WO2012136824A1 · 2012 [cited by applicant]
WO WO2012145493A1 · 2012 [cited by applicant]
WO WO2013025779A1 · 2013 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026837A1 · 2013 [cited by applicant]
WO WO2013067492A1 · 2013 [cited by applicant]
WO WO2013181634A2 · 2013 [cited by applicant]
WO WO2014006058A1 · 2014 [cited by applicant]
WO WO2014087010A1 · 2014 [cited by applicant]
WO WO2014090795A1 · 2014 [cited by applicant]
WO WO2014138314A1 · 2014 [cited by applicant]
WO WO2014179664A2 · 2014 [cited by applicant]
WO WO2014194302A2 · 2014 [cited by applicant]
WO WO2015035606A1 · 2015 [cited by applicant]
WO WO2015073801A1 · 2015 [cited by applicant]
WO WO2015085847A1 · 2015 [cited by applicant]
WO WO2015112800A1 · 2015 [cited by applicant]
WO WO2015112900A1 · 2015 [cited by applicant]
WO WO2016149201A2 · 2016 [cited by applicant]
WO WO2016154628A1 · 2016 [cited by applicant]
WO WO2016176164A1 · 2016 [cited by applicant]
WO WO2017112797A1 · 2017 [cited by applicant]
WO WO2017134140A1 · 2017 [cited by applicant]
WO WO2018017020A1 · 2018 [cited by applicant]
WO WO2018075813A1 · 2018 [cited by applicant]
WO WO2019046815A1 · 2019 [cited by applicant]
WO WO2019075385A1 · 2019 [cited by applicant]
WO WO2019173636A1 · 2019 [cited by applicant]
WO WO2019177669A1 · 2019 [cited by applicant]
WO WO2019231846A1 · 2019 [cited by applicant]
WO WO2020014366A1 · 2020 [cited by applicant]
WO WO2020017962A1 · 2020 [cited by applicant]
WO WO2020019135A1 · 2020 [cited by applicant]
WO WO2020036977A1 · 2020 [cited by applicant]
WO WO2020043188A1 · 2020 [cited by applicant]
WO WO2020208054A1 · 2020 [cited by applicant]
WO WO2020217226A1 · 2020 [cited by applicant]
WO WO2021216790A1 · 2021 [cited by applicant]
Marabelle et al. Intratumoral immunotherapy: using the tumor as the remedy. Annals of Oncology (2017), 28(Suppl. 12), xii33-xii43. (Year: 2017). [cited by examiner]
Cellosaurus entry to MVX-1 (first published 2022; retrieved from https://www.cellosaurus.org/CVCL_C3M8). (Year: 2022). [cited by examiner]
Leaf et al. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma. J Immunother (2017), 40(9), 315-322. (Year: 2017). [cited by examiner]
Santegoets et al. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother (2006), 55, 1480-1490. (Year: 2006). [cited by examiner]
Van de Loosdrecht et al. A novel allogeneic off-the-shelf dendritic cell vaccine for postremission treatment of elderly patients with acute myeloid leukemia. Cancer Immunology, Immunotherapy (2018), 67, 1505-1518. (Year… [cited by examiner]
Sarova et al. Characterization of Chromosome 11 Breakpoints and the Areas of Deletion and Amplification in Patients with Newly Diagnosed Acute Myeloid Leukemia. Genes, Chromosomes, & Cancer (2013), 52, 619-635. (Year: 2… [cited by examiner]
Aerts-Toegaert et al., “CD83 expression on dendritic cells and T cells: Correlation with effective immune responses”, European Journal of Immunology, 37:686-695, 2007. [cited by applicant]
Agarwal et al., In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes Molecular Therapy 28(8):1783-1794 (2020). [cited by applicant]
Alemany, “Oncolytic Adenoviruses in Cancer Treatment”, Biomedicines 2:36-49, 2014. [cited by applicant]
Alibakhshi et al., “Targeted cancer therapy through antibody fragments-decorated nanomedicines”, J Control Release, 2017, 268: 323-334. [cited by applicant]
Alvey et al., “SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors”, Current Biology, 27(14):2065-207, 2017. [cited by applicant]
Amir et al., “PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer”, Clinical Cancer Research, 17(17):5615-5625, 2011. [cited by applicant]
Andtbacka et al., “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma”, Journal of Clinical Oncology, 2015, 22(25): 2780-2788. [cited by applicant]
Anguille et al., “Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia”, Blood, Oct. 2017, 130(15): 1713-1721. [cited by applicant]
Baars et al., “Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients”, Annals of Oncology, 11(8):965-970, 2000. [cited by applicant]
Bell et al., “Crystal structure of nucleotide-free diphtheria toxin”, Biochemistry, 1997, 36(3): 481-488. [cited by applicant]
Bengala, et al., Mobilization; Collection, and Characterization of Peripheral Blood Hemopoietic Progenitors after Chemotherapy with Epirubicin, Paclitaxel, and Granulocyte-Colony Stimulating Factor Administered to Patie… [cited by applicant]
Bergmann et al., “An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein”, Eur J Immunol., 1993, 23(11): 2777-2781. [cited by applicant]
Bernhard et al., Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood, Cancer Research, 1995, pp. 1099-1104, vol. 55. [cited by applicant]
Bhaya et al., “CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation”, Annual Review Genetics, 45:273-297, 2011. [cited by applicant]
Bikard et al., “Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system”, Nucleic Acids Research, 41(15):7429-7437, 2013. [cited by applicant]
Bommareddy et al., “Integrating oncolytic viruses in combination cancer immunotherapy”, Nature Reviews Immunology, 2018, 18: 498-513. [cited by applicant]
Brocks et al., “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells”, Immunotechnology 3(3):173-184 (1997). [cited by applicant]
Bürdek et al., “Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation”, Journal of Translational Medicine, 8(90):1-13, 2010. [cited by applicant]
Buzzi et al., “Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin”, Cancer Res., Dec. 1974, 34(12): 3481-3486. [cited by applicant]
Buzzi et al., “CRM197: Effects of intravenous administration to advanced cancer patients”, Cancer Res., Apr. 2004, 64(7 Supplement): 878. [cited by applicant]
Buzzi et al., “Diphtheria toxin in cancer therapy”, The Lancet, 1974, 1(7858): 628-629. [cited by applicant]
Buzzi, “Diphtheria toxin treatment of human advanced cancer”, Cancer Res., 1982, 42(5): 2054-2058. [cited by applicant]
Buzzi, et al., “CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients”, Cancer Immunol. Immunother., 2004, 53: 1041-1048 (2004). [cited by applicant]
Buzzi, et al., “CRM197 and cancer: Effects of intratumoral administration”, Therapy, Sep. 2004, 1(1): 61-66. [cited by applicant]
Buzzi, et al., “CRM197; Effects of intravenous administration to advanced cancer patients”, American Association for Cancer Research, 2004, 64(7), Supplement. [cited by applicant]
Cermak et al., “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting”, Nucleic Acids Research, 39(12):e82-e82, 2011. [cited by applicant]
Chang et al., “A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and ß T-cell receptor extracellular segments”, PNAS USA 91:11408-11412 (1994). [cited by applicant]
Chao et al., “Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies”, Frontiers in Oncology, vol. 9, Art. 1380, pp. 1-9, 2019. [cited by applicant]
Cheever et al., “The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research”, Clinical Cancer Research, 15(17):5323-5337, 2009. [cited by applicant]
Chen et al., “Enhanced proofreading governs CRISPR-Cas9 targeting accuracy”, Nature, 550(7676):407-410, 2017. [cited by applicant]
Chervin et al., “Engineering higher affinity T cell receptors using a T cell display system”, The Journal of Immunology Methods 339(2):175-184 (2008). [cited by applicant]
Cho et al., “Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease”, Nature Biotechnology, 31(3):230-232, 2013. [cited by applicant]
Chothia et al., “The outline structure of the T-cell αß receptor”, The EMBO Journal 7(12):3745-3755 (1988). [cited by applicant]
Cignetti et al., CD34+ Acute Myeloid and Lymphoid Leukemic Blasts Can Be Induced to Differentiate Into Dendritic Cells, Blood, 1999, pp. 2048-2055, vol. 94. [cited by applicant]
Cohen et al., “Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR”, The Journal of Immunology 175:5799-5808 (2005). [cited by applicant]
Cong et al., “Multiplex Genome Engineering using CRISPR/Cas Systems”, Science, 339(6121):819-823, 2013. [cited by applicant]
Cougot et al., “'Cap-tabolism”, Trends in Biochemical Science 29(8):436-444, (2004). [cited by applicant]
Cripe et al., “Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients”, Molecular Therapy, 2015, 23(3): 602-608. [cited by applicant]
Danthinne et al., Production of first generation adenovirus vectors: a review, Gene Therapy, 7(20):1707-1714, 2000. [cited by applicant]
Davila et al., “CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia”, PLOS ONE 8(4):e61338 (2013). [cited by applicant]
Davis et al., “Basic Methods in Molecular Biology,” 1986. [cited by applicant]
Davodeau et al., “Secretion of Disulfide-linked Human T-cell Receptor γδ Heterdimers”, The Journal of Biological Chemistry 268(21):15455-15460 (1993). [cited by applicant]
DCPRIME BV, “Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia”, ClinicalTrials.gov Identifier: NCT01373515, Retrieved from: <<https://clinicaltrials.gov/ct2/show/NCT01373515?term=NCT01373515&d… [cited by applicant]
De Gruijil et al., “Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study”… [cited by applicant]
Elango et al., “Optimized transfection of mRNA transcribed from a d(A/T) [cited by applicant]
EPO Comms, EP 08826916.2, dated Jan. 24, 2011, Jul. 20, 2012, and May 11, 2012. [cited by applicant]
Erben et al., “CS-1, A Novel c-kithi+ Acute Myeloid Leukemia Cell Line With Dendritic Cell Differentiation Capacity and Absent Immunogenicity”, International Journal of Cancer, 105(2):232-240, 2003. [cited by applicant]
Ferlini et al.; A New Method to Evaluate in vitro Myelotoxicity of Antitumour Agents in the First Steps of Drug Development; Pharmacology & Toxicology 2001, 89; 231-236. [cited by applicant]
Ferrari et al.; Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard-or high-dose chemotherapy plus granulocyte-colony stimulating factor; Cancer Immunol Immunother; 2003; … [cited by applicant]
Fife et al., “Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist”, The Journal of Clinical Investigation 116(8):2252-2261 (2006). [cited by applicant]
Fiorentini et al., “Clinical experience of treatment of metastatic melanoma and solid tumours adopting a derivative of diphtheria toxin: cross-reacting material 197”, In Vivo, 2013, 27(2): 197-202. [cited by applicant]
Frietze et al., “Engineering virus-like particles as vaccine platforms”, Curr Opin Virol., 2016, 18: 44-49. [cited by applicant]
Gaj et al., “ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering”, Trends in Biotechnology, Jul. 2013, 31(7): 1-20, (Epub May 9, 2013). [cited by applicant]
Galluzzi et al., “Trial watch: Dendritic cell-based interventions for cancer therapy”, Oncolmmunology, 1(7):1111-1134, 2012. [cited by applicant]
Gao et al., “Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1”, Blood, 95(7):2198-2203, 2000. [cited by applicant]
Garboczi et al., “Assembly, Specific Binding, and Crystallization of a Human TCR-αß with an Antigenic Tax Peptide from Human T Lymphotropic Virus Type 1 and the Class I MHC Moledule HLA-A2 [cited by applicant]
Garboczi et al., “Structure of the complex between human T-cell receptor, viral peptide and HLA-A2”, Nature 384(6605):134-141 (1996). [cited by applicant]
Garfall et al., “T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma”, Blood Advances 3(19):2812-2815 (2019). [cited by applicant]
Geha et al., “The genetic basis of immunoglobulin-class switching”, N Engl J Med., 1994, 330(14): 1008-1009. [cited by applicant]
Gilbert et al., “CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes”, Cell, 154(2):442-451, 2013. [cited by applicant]
Gillis et al., “Contribution of human FcgRs to disease with evidence from human polymorphisms and transgenic animal studies”, Frontiers in Immunology 5:254 (2014). [cited by applicant]
Giomarelli et al., “Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-l”, Thromb Haemost 97(6):955-964 (2007). [cited by applicant]
Golden et al., “High-level production of a secreted, heterodimeric αß murine T-cell receptor in [cited by applicant]
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA”, Virology, 1973, 52(2): 456-467. [cited by applicant]
Greiner et al., “High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma”, Haematologica, 95(7):1191-1197, 2010. [cited by applicant]
Greiner et al., “Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T Cells of HLA-A2-positive patients with acute myeloid leukemia”, B… [cited by applicant]
Grossardt et al., “Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine”, Human Gene Therapy, 2013, 24: 644-654. [cited by applicant]
Haddad, “Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery”, Frontiers in Immunology, 2017, 7: 96. [cited by applicant]
He et al., “CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo”, Journal of Experimental & Clinical Cancer Research, 2010, … [cited by applicant]
Hermans et al., “The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo”, Journal of Immunological Methods 285(1):25-40 (2004). [cited by applicant]
Hermanson et al., “Utilizing chimeric antigen receptors to direct natural killer cell activity”, Frontiers in Immunology 6(195):1-6 (2015). [cited by applicant]
Hirooka et al., “Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancr… [cited by applicant]
Ho et al., “Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties”, Biochima et Biophysica Acta 1638(3):257-266 (20… [cited by applicant]
Holler et al., “In vitro evolution of a T cell receptor with high affinity for peptide/MHC”, PNAS USA 97(10):5387-5392 (2000). [cited by applicant]
Holler et al., “TCRs with high affinity for foreign pMHC show self-reactivity”, Nature Immunology 4(1):55-62 (2003). [cited by applicant]
Howells et al., “Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer”, Front Oncol., 2017, 7: 195. [cited by applicant]
Hu et al., “Evolved Cas9 variants with broad PAM compatibility and high DNA specificity”, Nature, 556(7699):57-63, 2018. [cited by applicant]
Huang et al., “MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47”, Molecular Cancer, Jan. 24, 2018, 17(12): 1-6. [cited by applicant]
Huck et al., “Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes”, Nucleic Acids Research 14(4):1779-1789 (1986). [cited by applicant]
Hudecek et al., “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity”, Cancer Immunology Research 3(2):125-135 (2015). [cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Hutzler et al., “Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles”, Scientific Reports, 2017, 7: 16892. [cited by applicant]
Hwang et al., “Controlled differentiation of stem cells”, Advanced Drug Delivery Reviews, 60(2):199-214, 2007. [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/IB2020/053898, mailed Jul. 2, 2020. [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/IB2021/052542, mailed Jun. 25, 2021. [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/IB2021/055822, mailed Sep. 30, 2021. [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/NL2019/050451, mailed Oct. 4, 2019. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2008/065391, mailed Feb. 26, 2009. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2013/076067, mailed Feb. 5, 2014. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2021/052543, mailed May 31, 2021. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2021/060233, mailed Apr. 4, 2022. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/IB2022/052211 mailed Jul. 19, 2022. [cited by applicant]
Jinek et al., “RNA-programmed genome editing in human cells”, eLife, 2:e00471, 2013. [cited by applicant]
Jores et al., “Resolution of hypervariable regions in T-cell receptor ß chains by a modified Wu-Kabat index of amino acid diversity”, PNAS USA 87:9138-9142 (1990). [cited by applicant]
Jurincic-Winkler et al., “Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma”, Anticancer Res., 1996, 16(4A): 2105-2110. [cited by applicant]
Kleinstiver et al., “High-fidelity CRISPR-CAS9 variants with undetectable genome-wide off-targets,” Nature, 529(7587):490-495, 2016. [cited by applicant]
Kloosterman et al., “Deciphering the pathogenic consequences of chromosomal aberrations in human genetic disease”, Molecular Cytogenetics, 7(100):1-12, 2014. [cited by applicant]
Kochenderfer et al., “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor”, Journal of Immunotherapy 32(7):689-702 (2009). [cited by applicant]
Kohrt et al., “Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation”, Blood, 118(19):5319-5329, 2011. [cited by applicant]
Kotb, “Bacterial Pyrogenic Exotoxins as Superantigens”, Clinical Microbiology Reviews 8(3):411-426 (1995). [cited by applicant]
Koup et al., “Vaccine design for CD8 T lymphocyte responses”, Cold Spring Harb Perspect Med., 2011, 1(1): a007252. [cited by applicant]
Krug et al., “WT1 Peptide Vaccinations Induce CD4 and CD8 T Cell Immune Responses in Patients With Mesothelioma and Non-small Cell Lung Cancer”, Cancer Immunology, Immunotherapy, 59(10):1467-1479, 2010. [cited by applicant]
Kruisbeek, “Adoption of Cryostor® in Manufacturing of a Dendritic Cell Vaccine Platform”, BioPreservation Today®, vol. 3, Issue 1, p. 10, 2011. [cited by applicant]
Kudo-Saito, et al., “Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules”, Clin Cancer Res., 2004, 10… [cited by applicant]
Kurtzberg et al., “CD7+, CD4-, CD8-Acute Leukemia: A Syndrome of Malignant Pluripotent Lymphohematopoietic Cells”, Blood, 73(2):381-390, 1989. [cited by applicant]
Lal et al., “Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy”, Cancer Gene Ther., 2018, 25: 216-226. [cited by applicant]
Larsson et al., “Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells”, Immunology, 117:156-166, 2006. [cited by applicant]
Laurell et al., “Intratumorally injection pro-inflammatory allogeneic dendritic cells as immune enhancers: a first in-human study in unfavourable risk patients with metastatic renal cell carcinoma”, Journal for Immunoth… [cited by applicant]
Lawler et al., “Oncolytic Viruses in Cancer Treatment: A Review”, JAMA Oncol. Review, 2017, 3(6): 841-849. [cited by applicant]
Lee et al., “ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells”, Biology of Blood and Marrow Transplantation 25:625-638, doi.org/10.1016/j.bbmt.2018.12.7… [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains”, Developmental and Comparative Immunology 27:55-77 (2003). [cited by applicant]
Li et al., “Directed evolution of human T-cell receptors with picomolar affinities by phage display”, Nature Biotechnology 23(3):349-354 (2005). [cited by applicant]
Li et al., “Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice”, Nature Communications, 11:581, 2020. [cited by applicant]
Liu et al., “Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential”, PLoS One, 10(9): e0137345, 2015. [cited by applicant]
Logtenberg et al., “Glutaminyl cyclase in an enzymatic modifier of the CD47-SIRPα axis and target for cancer immunotherapy”, Nat. Med., 25(4):612-619, 2019. [cited by applicant]
Lu et al., “Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies”, OncoTargets and Therapy, 13:9323-9331, 2020. [cited by applicant]
Lundstrom, K., “Viral Vectors in Gene Therapy”, Diseases 6(2):42, DOI: 10.3390/diseases6020042 (2018). [cited by applicant]
Ma et al., “Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential”, Journal of Nanobiotechnology, 18:12, pp. 1-15, 2020. [cited by applicant]
Mali et al., “CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering”, Nature Biotechnology, 31(9):833-838, 2013. [cited by applicant]
Mali et al., “RNA-Guided Human Genome Engineering via Cas9”, Science, 339(6121):823-826, 2013. [cited by applicant]
Malito et al., “Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197”, Proc Natl Acad Sci U S A, 2012, 109(14): 5229-5234. [cited by applicant]
Marelli et al., “Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer”, Frontiers in Immunology, 2018, 9: 866. [cited by applicant]
Masterson et al., “MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors”, Blood, 100(2):701-703, 2002. [cited by applicant]
May et al., “Peptide Epitopes From the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells”, Clinical Cancer Research, 13(15):4547-4555, 2007. [cited by applicant]
Mishra et al., “Structural and immunological characterization of [cited by applicant]
Mitchell et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients”, Nature 519(7543):366-369 (2015). [cited by applicant]
Miyamoto et al., “Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy”, Cancer Science 97(5):341-347 (2006). [cited by applicant]
Miyamoto, et al., “New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule”, Anticancer Res., 2007, 27(6A): 3713-3721. [cited by applicant]
Mohan et al., “Applications of chemokines as adjuvants for vaccine immunotherapy”, Immunobiology, 2018, 223(6-7): 477-485. [cited by applicant]
Moldenhauer et al., “Tumor Necrosis Factor Alpha-Stimulated Endothelium: An Inducer of Dendritic Cell Development from Hematopoietic Progenitors and Myeloid Leukemic Cells”, Stem Cells, 22(2):144-157, 2004. [cited by applicant]
Moosmayer et al., “A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity”, Therapeutic Immunology, 2(10):31-40 (1995). [cited by applicant]
Morris, “Cryopreservation of Animal and Human Cell Lines”, Methods in Molecular Biology, vol. 368: Cryopreservation and Freeze-Drying Protocols, 2nd Ed. (J. G. Day and G. N. Stacey eds.), Humana Press Inc. Totowa, N.J.,… [cited by applicant]
Moya et al., “Inhibition of Coated Pit Formation in Hep [cited by applicant]
Mumtaz et al., “Design of liposomes for circumventing the reticuloendothelial cells”, Glycobiology 1(5):505-510 (1991). [cited by applicant]
Murata et al., “CD47-signal regulatory protein a signaling system and its application to cancer immunotherapy”, Cancer Sci., Aug. 2018, 109(8): 2349-2357 (Epub Jul. 4, 2018). [cited by applicant]
Nacheva et al., “Preventing nondesired RNA-primed RNA extension catalyzed by T7 RNA polymerase”, Eur. J. Biochem. 270:1485-1465 (2003). [cited by applicant]
Nagasawa et al., “DCP-001 stimulates T cell proliferation and increases memory CD4 + T cells in OC patients' PBMC Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP… [cited by applicant]
Nam, et al., “Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy”, Anticancer Res., 2016, 36(7): 3651-3657. [cited by applicant]
Narita et al., “WT1 Peptide Vaccination in Combination With Imatinib Therapy for a Patient With CML in the Chronic Phase”, International Journal of Medical Sciences, 7(2):72-81, 2010. [cited by applicant]
Neelapu et al., “Chimeric antigen receptor T-cell therapy—assessment and management of toxicities”, Nat Rev Clin Oncology 15(1):47-62 (2018). [cited by applicant]
Neuhaus et al., Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro; Journal of Neuroimmunology 168: 128-137 (2005). [cited by applicant]
Nguyen-Hoai et al., “CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model”, Cancer Gene Therapy, 2012, 19: 69-76. [cited by applicant]
Nijman et al., “Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (ALISON)”, Feb. 4,… [cited by applicant]
Ochsenreither et al., “Wilms Tumor Protein 1 (WT1) Peptide Vaccination—induced Complete Remission in a Patient With Acute Myeloid Leukemia is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and … [cited by applicant]
Olusanya et al., “Liposomal Drug Delivery Systems and Anticancer Drugs”, Molecules, 2018, 23(4): 907. [cited by applicant]
Palucka et al., “Recent Developments in Cancer Vaccines”, The Journal of Immunology, 186(3):1325-1331, 2011. [cited by applicant]
Park et al., “Are All Chimeric Antigen Receptors Created Equal?”, Journal of Clinical Oncology 33(6):651-653 (2015). [cited by applicant]
Parkhurst et al., “Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells”, Clinical Cancer Research 15(1):169-180 (2… [cited by applicant]
Peter et al., “Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats”, J Cachexia Sarcopenia Muscle Aug. 12, 2012. [cited by applicant]
Peter et al., “scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the ß [cited by applicant]
Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression”, Cell, 152(5): 1173-1183, 2013. [cited by applicant]
Quintarelli et al., “Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia”, Blood, 112(5):1876-1885, 2008. [cited by applicant]
Quintarelli et al., “High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells”, Blood, 117(12):3353-3362, 2011. [cited by applicant]
Rezvani et al., “Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies”, Blood, 111(1):236-242, 2008. [cited by applicant]
Rezvani et al., “T-Cell Responses Directed against Multiple HLA-A* 0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Character… [cited by applicant]
Rosato et al., “Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy”, Nature Communications 10:567 (2019). [cited by applicant]
Rosenberg “Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know”, Nat Rev Clinical Oncology 8(10):577-585 (2011). [cited by applicant]
Rosenfeld et al., “WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies”, Leukemia, 17:1301-1312, 2003. [cited by applicant]
Santegoets et al., “A CD34+ Human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+ Langerhans cell precursor”, Journal of Leukocyte Biology, 80:1337-1344, 2006. [cited by applicant]
Santegoets et al., “In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line”, Cancer Immunology, Immunotherapy, 55:1480-1490, 2006. [cited by applicant]
Saxena et al., “Re-emergence of Dendritic Cell Vaccines for Cancer Treatment”, Trends in Cancer, 2018, 4:2: 119-137. [cited by applicant]
Schenborn et al., “A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure”, Nucleic Acids Research 13:6223-36 (1985). [cited by applicant]
Scheraga “Predicting Three-Dimensional Structures of Oligopeptides” Reviews in Computational Chemistry 2:73-142 (1992). [cited by applicant]
Schlueter et al., “Specificity and Binding Properties of a Single-chain T Cell Receptor”, J. Mol. Biol. 256:859-869 (1996). [cited by applicant]
Schmitt et al., “Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules”, Experimental Hematology, 34(12):1709-1719, 2006. [cited by applicant]
Schmitt et al., “RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses”, The Journal of the American Society of H… [cited by applicant]
Shankar et al., “Interferon-[gamma] Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent T h 1 Immune Responses”, Oct. 10, 2003, Retrieved from the Internet: URL:https://link.springe… [cited by applicant]
Shen et al. “Engineering Peptide Linkers for scFv Immunosensors”, Anal. Chem. 80(6):1910-1917 (2008). [cited by applicant]
Shieh et al., “Transgenic Expression of Single-Chain Anti-CTLA-4 Fv on ß Cells Protects Nonobese Diabetic Mice from Autoimmune Diabetes”, The Journal of Immunology 183(4):2277-2285 (2009). [cited by applicant]
Slaymaker et al., “Rationally engineered Cas9 nucleases with improved specificity”, Science, 351(6268): 84-88, 2016. [cited by applicant]
Smith, et al., “In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers”, Nat. Nanotechnology 12(8):813-820 (2017). [cited by applicant]
Sockolosky et al., “Durable antitumor responses to CD47 blockade require asaptive immune stimulation”, PNAS, 113(19):E2646-2654, 2016. [cited by applicant]
Sommandas et al., “Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours”, Journal for Immunotherapy of Cancer 7(Suppl. 1):P687 (2019) & 34 [cited by applicant]
Sommermeyer et al., “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo”, Leukemia 30(2):492-500 (2016). [cited by applicant]
Stepinski et al., “Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl(3′-deoxy)GpppG”, RNA, 7:1468-1495 (2001). [cited by applicant]
Stickings, et al., “Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine”, Infect Im… [cited by applicant]
Subhadra et al., “Inducing Tumor Suppressive Microenvironments through Genome Edited CD47-/- Syngeneic Cell Vaccination”, Scientific Reports, Dec. 27, 2019, 9(1): 20057. [cited by applicant]
Suhrbier, “Multi-epitope DNA vaccines”, Immunol Cell Biol., 1997, 75(4): 402-408. [cited by applicant]
Tack et al., “Phenotypic and genomic analysis of an exceptional case of enteropathy associated T-cell lymphoma”, Leukemia Research, 34(8):e183-e189, 2010. [cited by applicant]
Tacken et al., “Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody”, Blood, 2005, 106(4): 1278-1285. [cited by applicant]
Tan et al., “Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins”, PNAS USA 87(1): 162-166 (1990). [cited by applicant]
Teachey et al. “Identification of Predictive Biomarkers for Cytokine Release Syndrome afer Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia”, Cancer Discovery 6(6):664-679 (2016). [cited by applicant]
Themeli et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy”, Nature Biotechnology 31(10):928-933 (2013). [cited by applicant]
Thurner et al., “Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application”, Journal of Immunological Methods, 223(1):1-15, 1999. [cited by applicant]
Töpfer et al., “DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy”, The Journal of Immunology 194(7):3201-3212 (2015). [cited by applicant]
Triozzi et al., “Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer”, Cancer, 2000, 89(12): 2646-2654. [cited by applicant]
Tseng et al., “Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-call response”, PNAS, 110(27):11103-11108, 2013. [cited by applicant]
Tsukahara et al., “CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models”, Biochem Biophys Res Commun 438(1):84-89 (2013). [cited by applicant]
Twumasi-Boateng et al., “Oncolytic viruses as engineering platforms for combination immunotherapy”, Nature Reviews Cancer 18:419-432 (2018). [cited by applicant]
Uchida et al., “Mutation in the structural gene for diphtheria toxin carried by temperate phage”, Nat New Biol., 1971, 233(35): 8-11. [cited by applicant]
Ud Din et al., “Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors”, Int J Nanomedicine, 2017, 12: 7291-7309. [cited by applicant]
Ueno et al., “Harnessing Human Dendritic Cell Subsets for Medicine”, Immunological Reviews, 234(1):199-212, 2010. [cited by applicant]
Van De Ven et al., “Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy”, Cancer Immunology, Immunotherapy, Springer, … [cited by applicant]
Van Helden et al., “Human and murine model cell lines for dendritic cell biology evaluated”, Immunology Letters, 117(2):191-197, 2008. [cited by applicant]
Van Nuffel et al., “Loading of dendritic cells for immunotherapy”, ISBT Science Series, 2013, 8: 161-164. [cited by applicant]
Van Tendeloo et al., “Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination”, PNAS, 107(31):13824-13829, 2010. [cited by applicant]
Varela-Rohena et al., “Control of HIV-1 immune escape by CD8 T-calls expressing enhanced T-cell receptor”, Nat Med. 14(12):1390-1395 (2008). [cited by applicant]
Vermeij et al., “Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer”, Clinical and Developmental Immunology, vol. 2010, Article ID 891505, pp. 1-8. 2010. [cited by applicant]
Vigneron et al., “Database of T cell-defined human tumor antigens: the 2013 update”, Cancer Immunity, 2013, 13: 15. [cited by applicant]